Turns out, we were sitting on a great idea all along.
To revolutionize health and wellness through in-home health monitoring, leveraging technology to enhance the efficiency of caregivers while effectively reducing healthcare costs for our patients and payers.
Empower the world’s caregivers with access to reliable, consistent vital signs to improve and extend the lives of those we love.
Where it all started…
Heart Seat® is invented by Nicholas Conn, PhD
First peer reviewed publication
Heart Health Intelligence (HHI) was incorporated
Second peer reviewed publication
Heart Health Intelligence closed its $2.2M Seed Round.
HHI raises $14m Series A led by General Catalyst and Outsiders Fund
HHI rebrands to Casana
Casana opens headquarter office at 150 Metro Park in Rochester
Casana opens commercial office in Boston
Casana raises $30m Series B led by Morningside
Casana receives FDA Clearance for SpO2 and Heart Rate
Why Toilet Tech Is a New Fitness Frontier – CNET
How you use the bathroom may tell you a lot about your general well-being, including how hydrated you are, the health of your gut microbiome and more. At CES 2023, tech companies watched your trip to the bathroom at a different angle, showcasing devices that take your blood pressure, check for nutritional deficiencies and gather other data.View Article
Smart Toilet Market in North America report 2028 | Size, Share, Growth by Business Market Insights
The North America smart toilet market is expected to grow from US$ 1,790.86 million in 2022 to US$ 3,457.64 million by 2028. It is estimated to grow at a CAGR of 11.6% from 2022 to 2028.View Article
Boldly Growing: A Start-Up Founder’s Guide to Sustainable Success
Austin led the company through its acquisition by Vista Equity Partners in 2017, and subsequent $4B+ IPO in 2020. Austin is a Forbes 30 Under 30, was named Ernst & Young Technology Entrepreneur of the Year in 2016, and earned recognition as one of the nation’s top 50 philanthropists in 2017.View Article
As the founder and former CEO of Datto, an innovative provider of comprehensive backup, recovery, and business continuity solutions, Austin led the company through its acquisition by Vista Equity Partners in 2017, and subsequent IPO in 2020.
Austin is a Forbes 30 Under 30, was named Ernst & Young Technology Entrepreneur of the Year …
With more than 20 years of experience developing innovations and systems that improve health, Dr. Anand’s leadership experience includes public health, research, consumer health technology, and clinical informatics. Prior to joining Casana, Anand served as the Chief Medical Officer at Well, the on-demand healthcare guidance platform, and Withings, a world leader …
Nick completed his PhD in Engineering in 2016 at Rochester Institute of Technology, where he developed Casana’s technology – a toilet seat-based cardiovascular monitoring system. He founded Casana in 2018.
His expertise spans business development, algorithm development, cardiovascular monitoring, medical devices, ultra-low power systems, physiology, and signal processing. Nick also holds a …
Borkholder has spent nearly three decades as an innovator in both industry and academia, developing medical device technologies spanning DNA diagnostics (Cepheid), ultrasound (ZONARE), implantable devices (RIT) and cardiovascular monitoring (RIT / Casana). As the Bausch and Lomb Professor of Microsystem Engineering at RIT, he led the establishment of an institute-wide …
Dave has published over 75 journal and conference proceedings and holds 24 patents related to cell-based biosensors, DNA analysis, blast dosimetry, and cardiovascular monitoring.
Prior to Casana, Olivia was an investor on the early-stage team at General Catalyst. Her investment focus was on early‐stage founders building transformative companies at the intersection of software and healthcare. She served on the Board of multiple health tech startups.
Olivia’s experience also includes Capgemini Consulting, where she …
Prior to joining Casana, Kara has served as a Regulatory and Quality leader at several New England-based Medical Device companies for nearly two decades.
Kara’s particular strengths and expertise lie in Regulatory strategy, compliance, and helping companies achieve and maintain domestic and international market access for new and innovative medical …
Board of Directors
Dr. Leiden is a physician and scientist who, for the last 40 years, has dedicated his career to improving the lives of people with serious diseases. His experience spans all aspects of the biotech and pharmaceutical industries. He is currently the Executive Chairman of Vertex Pharmaceuticals, where he has served as …
In addition to his responsibilities at Vertex, Dr. Leiden is currently Chairman of Casana, a home health monitoring company, and Chairman of Tmunity Therapeutics, a biotechnology company developing novel T-cell immunotherapies to treat solid tumors. He is Vice Chairman of the Massachusetts Competitive Partnership and a director of the Massachusetts Mutual Life Insurance Company. Dr. Leiden also serves on the board of fellows of Harvard Medical School and as co-chair of Massachusetts Governor Charlie Baker’s STEM Advisory Council and Digital Health Council. He is a fellow of the American Academy of Arts and Sciences and an elected member of the National Academy of Medicine, the American Society of Clinical Investigation and the American Association of Physicians. He received his B.A., M.D. and Ph.D. degrees with honors from the University of Chicago.
Dr. Khan Siddiqui is the Chief Medical Officer and Chief Strategy Officer of Hyperfine, the world’s first FDA-cleared, truly portable Point of Care MRI. He brings his 25 years of experience as a trained clinician and serial healthcare technology entrepreneur to his work leading the strategic direction of the company. …
Dr. Siddiqui holds multiple patents for technology in areas of deep learning, AI, image processing, data visualization, as well as securing patient information handling and health records. His recent research includes large scale studies on the impact of ubiquitous access to health in combination with artificial intelligence and persuasive technologies to improve healthcare outcomes. Dr. Siddiqui particularly focuses on how to secure and protect data while enabling development of deep learning models to accelerate practical applications of AI in healthcare.
Prior to founding higi in 2012, Dr. Siddiqui was a Physician Executive and Principal Program Manager at Microsoft where he was responsible for platform engineering and machine learning for the health solutions group. His Microsoft legacy includes stimulating computer vision and machine learning research that led to the development of the regression forest algorithms, which became the foundation technology in the Xbox Kinect. Dr. Siddiqui was also responsible for developing Microsoft’s cloud (Azure) based medical imaging products and infrastructure.
Prior to Microsoft, Dr. Siddiqui was Director of Center for Biomedical Imaging and Informatics at Johns Hopkins University, Program Director of Imaging Informatics and MRI Fellowship Programs at University of Maryland and also the founding chair of American College of Radiology’s Imaging Informatics and IT Commission. He is a graduate of the Aga Khan University Medical College in Pakistan, completed his training in Medicine at New York University, Radiology training at Geisinger Medical Center in Danville, PA, along with his fellowship in the Imaging Informatics at University of Maryland in Baltimore, MD. Dr. Siddiqui has published dozens of peer-reviewed papers and has given 100s of invited talks. Dr. Siddiqui is member of board of directors as well as advisory boards of various startups around the world and sits on various national committees on health care and medical imaging.
In his spare time, Dr. Siddiqui loves spending time with his family. He and his two sons can often be found exploring Chicago on bikes in between painting and SCUBA diving.
Paul Sagan is a senior advisor to, and an XIR (executive-in-residence) at, General Catalyst, representing the firm as a director of airSlate, Anaconda, and Section4. Paul is also a director of Moderna, and the lead independent director of VMware. Prior to General Catalyst, Paul served as president, CEO and vice …
A three-time Emmy Award winner for broadcast journalism, Paul serves as chairman of the board of ProPublica, and he is a Fellow of the American Academy of Arts & Sciences. In all of his roles, Paul leverages his broad leadership capabilities, investment experience, and skills as an operator to advise and support CEOs and founding teams, with a particular focus on internet infrastructure, software and services.
Stephen Bruso joined Morningside Ventures in 2019 and focuses on early-stage investments in thedigital health space. He has extensive experience providing operational and management oversight tocompanies. Mr. Bruso serves as a director for numerous private companies including CognitoTherapeutics, Curai Health, Suvera, Neuroelectrics, Huckleberry, Ieso Digital Health, Wellinks, CurveHealth, Koa Health, SimpliFed, …
Prior to joining Morningside, Mr. Bruso worked at a series of molecular diagnostics startups spun outfrom the Church Lab at HMS before transitioning to the software space where he led the developmentand commercialization of e-commerce platforms for SMBs. He received his MBA from Boston Universityin 2019, graduating magna cum laude. He received his BA from Emory University in 2009.
Scientific & Medical Advisory Board
As a renowned and widely published (more than 200 peer-reviewed publications) hypertension specialist, Dr. Flack has expertise in the diagnosis and treatment of secondary forms of hypertension, resistant hypertension and hypertension in African Americans. He is a board-certified internal medicine specialist and an American Society of Hypertension (ASH) …
Dr. Bakris is a Professor of Medicine and Director of the Am. Heart Assoc. Comprehensive Hypertension Center at the University of Chicago Medicine. He has published over 900 peer-reviewed articles and book chapters in the areas of diabetic kidney disease, hypertension, and nephropathy progression. He is the Editor or Co-Editor of 22 …
Milton Packer MD is currently Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center at Dallas. Dr. Packer is an internationally recognized clinical investigator who has made many seminal contributions to the field of heart failure, both in understanding its mechanisms and defining its rational management. His work has …
In recognition of these achievements, he received the Lewis Katz Lifetime Achievement Award from Columbia University College of Physicians and Surgeons. He has authored over 500 peer-reviewed publications and has been the overall Principal Investigator for 20 large-scale international trials of novel interventions in heart failure. He was a Founding Member and served a President of the Heart Failure Society of America (2000-2002), and he has served on numerous guidelines and standards committees for the American Heart Association and American College of Cardiology. Since 1986, he has been a primary consultant to the FDA on matters related to the design of clinical trials and the interpretation of clinical trial evidence.
Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN, is associate chief nursing officer for Cleveland Clinic’s Office of Nursing Research and Innovation, and a clinical nurse specialist in Cleveland Clinic’s Kaufman Center for Heart Failure in the Heart, Vascular & Thoracic Institute. With extensive …
Throughout her career, Dr. Albert has been influential in the healthcare industry actively volunteering on steering committees, work groups and task forces of many national healthcare organizations. She has published more than 315 peer-reviewed articles in nursing and medical journals, written book chapters and is a national and international presenter. She is the editor of a book (2016): Building and Sustaining a Hospital-Based Nursing Research Program (Springer). Additionally, she has received several professional awards and recognitions, holds 4 national nursing certifications, including being a board-certified nurse executive, is a Fellow at 3 organizations and is an adjunct associate professor at an Ohio-based school of nursing and a full professor at Aalborg University in Denmark. In 2015, she participated in a year-long AONE-Arizona State University Interprofessional Fellowship in Innovative Health Leadership.
Michael S. Parmacek, MD is the Frank Wister Thomas Professor of Medicine and Chair of the Department of Medicine at the Perelman School of Medicine at the University of Pennsylvania. Dr. Parmacek graduated magna cum laude from Tufts University and obtained his M.D. from Northwestern University Medical School. He …
Following his clinical training, Dr. Parmacek performed a postdoctoral research fellowship in molecular cardiology at the Howard Hughes Medical Institute at the University of Michigan. He was appointed to the faculty of the University of Michigan from 1987-1992 and the University of Chicago from 1992-1998, serving as Co-Director of the Cardiology fellowship training program. In 1998, Dr. Parmacek was recruited to the University of Pennsylvania as Chief of the Division of Cardiovascular Medicine. During his tenure (1998-2014), Penn’s Cardiovascular Medicine division ascended to the top tier of national programs. In 2005, Dr. Parmacek was appointed as the Director of the newly established University of Pennsylvania Cardiovascular Institute and served until 2017. In 2014, Dr. Parmacek was appointed as the 25th Chair of the University of Pennsylvania Department of Medicine; the nation’s first Department of Medicine.
Dr. Parmacek is internationally recognized for his pioneering research studies in cardiovascular cell and molecular biology. Over the course of his career, he has made multiple seminal discoveries that have impacted directly on understanding the molecular and genetic basis of congenital heart disease, aortic disease, and atherosclerosis. He has published over ninety manuscripts in high-impact journals including Science, Cell and the New England Journal of Medicine. Dr. Parmacek was chosen as an Established Investigator by the American Heart Association and he was elected Fellow of the AHA, American College of Cardiology and American College of Physicians. He also served as President of the Association of Professors of Cardiology. Dr. Parmacek has been elected to the American Society of Clinical Investigation and the American Association of Physicians. In 2009, Dr. Parmacek was appointed by the United States Secretary of Health and Human Services to the Advisory Council of the National Heart Lung and Blood Institute of the NIH.
Sign Up to Participate